DENTSPLY SIRONA (XRAY) CEO Scavilla receives 2.07M stock options and RSUs

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. President and CEO Daniel T. Scavilla reported equity compensation awards. He received stock options covering 2,066,600 shares, which vest in annual one-third increments over three years ending March 4, 2029, with an exercise price equal to 115% of the closing price on the grant date.

He also received 145,089 shares of common stock in the form of Restricted Stock Units, vesting one-third annually over the same three-year period ending March 4, 2029. Following these awards, his directly owned common stock holdings increased to 161,839.066 shares, and he directly holds 2,066,600 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scavilla Daniel T

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NC 28277

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO & Member of BOD

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		145,089(1)	A	$0	161,839.066	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.46	03/04/2026		A		2,066,600		03/04/2027(2)	03/04/2036	Common Stock	2,066,600	$0	2,066,600	D

Explanation of Responses:

1. Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.

2. Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 115% of the closing price of the Issuer's common stock as of the date of grant.

	/s/ Jessica Nielsen Causey, Attorney-in-Fact for Daniel T. Scavilla	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DENTSPLY SIRONA (XRAY) report for Daniel T. Scavilla?

DENTSPLY SIRONA reported that President and CEO Daniel T. Scavilla received grants of stock options and Restricted Stock Units. These awards increase his equity-based incentives and tie more of his compensation to the company’s future share performance over several years.

How many stock options were granted to the XRAY CEO in this Form 4?

Daniel T. Scavilla was granted 2,066,600 stock options. These options vest in annual one-third increments over three years ending on March 4, 2029, and have an exercise price equal to 115% of the common stock’s closing price on the grant date.

What Restricted Stock Unit (RSU) award did XRAY’s CEO receive?

The CEO received an award of 145,089 Restricted Stock Units. These RSUs vest in one-third installments annually over a three-year period ending March 4, 2029, providing him with additional common shares as they vest, subject to continued service and award terms.

How do the new equity awards affect Daniel T. Scavilla’s XRAY share ownership?

After the grant, Daniel T. Scavilla directly owns 161,839.066 shares of DENTSPLY SIRONA common stock. In addition, he directly holds 2,066,600 stock options, which may be exercisable over time as they vest according to the disclosed three-year vesting schedule.

Over what period do the XRAY CEO’s new equity awards vest?

Both the stock options and Restricted Stock Units vest in annual one-third installments over three years. The vesting period ends on March 4, 2029, meaning portions of the awards become available each year, aligning long-term incentives with company performance.

What is the exercise price structure for Daniel T. Scavilla’s new stock options?

The new stock options have an exercise price set at 115% of the closing price of DENTSPLY SIRONA’s common stock on the grant date. This structure requires future share price appreciation above that level for the options to deliver intrinsic value when exercised.